Polar Capital reports 5.28% stake in Arcutis

Polar Capital Holdings Plc and Polar Capital LLP reported a significant ownership position in Arcutis Biotherapeutics, Inc. common stock.

Rhea-AI Filing Summary

Polar Capital Holdings Plc and Polar Capital LLP reported a significant ownership position in Arcutis Biotherapeutics, Inc. common stock. They collectively beneficially own 6,606,945 shares, representing 5.28% of the outstanding common stock, with sole voting and dispositive power over these shares and no shared power.

The ownership percentage is calculated based on 125,083,374 shares outstanding of Arcutis Biotherapeutics as reported in the company’s Form 10-Q filed on May 6, 2026. The filing is made as a joint Schedule 13G by Polar Capital entities, with the joint filing statement executed by Chief Operating Officer Nicholas Farren.

Key Figures

Shares beneficially owned: 6,606,945 shares Percent of class: 5.28% Shares outstanding baseline: 125,083,374 shares +2 more

5 metrics

Shares beneficially owned 6,606,945 shares Arcutis Biotherapeutics common stock reported by Polar Capital entities

Percent of class 5.28% Ownership percentage of Arcutis common stock held by Polar Capital entities

Shares outstanding baseline 125,083,374 shares Arcutis common shares outstanding as reported in Form 10-Q on May 6, 2026

Sole voting power 6,606,945 shares Shares over which Polar Capital has sole voting power

Sole dispositive power 6,606,945 shares Shares over which Polar Capital has sole dispositive power

Key Terms

beneficially owned, Sole Voting Power, Sole Dispositive Power, Schedule 13G, +1 more

5 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 6,606,945.00"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"5 | Sole Voting Power 6,606,945.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Sole Dispositive Power financial

"7 | Sole Dispositive Power 6,606,945.00 8 | Shared Dispositive Power 0.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G regulatory

"joint filing statement pursuant to Rule 13d-1(k) on Schedule 13G"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

joint filing statement regulatory

"Exhibit I JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake in Arcutis Biotherapeutics (ARQT) does Polar Capital report?

Polar Capital reports beneficial ownership of 6,606,945 shares of Arcutis Biotherapeutics common stock, representing 5.28% of the class, based on 125,083,374 shares outstanding referenced from a Form 10-Q filed on May 6, 2026.

Who are the reporting persons in the Arcutis (ARQT) Schedule 13G?

The reporting persons are Polar Capital Holdings Plc and Polar Capital LLP. They jointly file the Schedule 13G and have a joint filing statement signed by Chief Operating Officer Nicholas Farren on behalf of the Polar Capital entities.

What voting and dispositive power does Polar Capital have over ARQT shares?

Polar Capital reports sole voting power and sole dispositive power over 6,606,945 shares of Arcutis Biotherapeutics. They report no shared voting power and no shared dispositive power over any Arcutis common stock in this filing.

How was Polar Capital’s 5.28% ownership in Arcutis (ARQT) calculated?

The 5.28% ownership figure is based on Polar Capital’s 6,606,945 beneficially owned shares relative to 125,083,374 shares outstanding of Arcutis common stock, with the outstanding share count taken from Arcutis’s Form 10-Q dated May 6, 2026.

What type of SEC filing did Polar Capital submit for its ARQT position?

Polar Capital submitted a Schedule 13G, which is a beneficial ownership report for investors holding more than 5% of a company’s equity. This filing reports a 5.28% stake in Arcutis Biotherapeutics common stock by Polar Capital entities.

Who signed the joint Schedule 13G related to Arcutis (ARQT)?

The joint Schedule 13G was signed by Nicholas Farren, Chief Operating Officer, on behalf of Polar Capital Holdings PLC, Polar Capital LLP, and Polar Capital Funds PLC - Biotechnology Fund, acknowledging responsibility for their respective information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 06:20 AM Accepted by SEC EDGAR 08/14/2026 - 06:20 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Arcutis Biotherapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

03969K108

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 03969K108

1

Names of Reporting Persons

Polar Capital Holdings Plc

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,606,945.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,606,945.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,606,945.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.28 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP Number(s): 03969K108

1

Names of Reporting Persons

Polar Capital LLP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 6,606,945.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,606,945.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,606,945.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.28 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Arcutis Biotherapeutics, Inc.
(b)	Address of issuer's principal executive offices: 2945 TOWNSGATE ROAD SUITE 110, WESTLAKE VILLAGE, CALIFORNIA, 91361
Item 2.
(a)	Name of person filing: Polar Capital Holdings Plc Polar Capital LLP
(b)	Address or principal business office or, if none, residence: 16 Palace Street London, SW1E 5JD George's Court, 54-62 Townsend Street Dublin 2, Ireland
(c)	Citizenship: United Kingdom
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP Number(s): 03969K108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6,606,945.00
(b)	Percent of class: 5.28%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 6,606,945.00
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 6,606,945.00
	(iv) Shared power to dispose or to direct the disposition of: 0 Based on 125,083,374 shares outstanding as reported in the Issuer's Form 10-Q on May 6, 2026.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Information for each Subsidiary is incorporated on the respective cover pages.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Polar Capital Holdings Plc

Signature:	/s/ Nicholas Farren
Name/Title:	Nicholas Farren - Chief Operating Officer
Date:	08/14/2026

Polar Capital LLP

Signature:	/s/ Nicholas Farren
Name/Title:	Nicholas Farren - Chief Operating Officer
Date:	08/14/2026

Exhibit Information

Exhibit I JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Polar Capital Holdings PLC By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer Polar Capital LLP By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer Polar Capital Funds PLC - Biotechnology Fund By: /s/ Nicholas Farren Name: Nicholas Farren Title: Chief Operating Officer